Zimbabwe has turned down a significant American healthcare agreement worth 367 million US dollars (£272m) spanning five years due to Washington's request for sensitive biological samples.
The decision came to light after a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "skewed".
An official spokesperson later stated that the US was requesting biological samples for research and commercial purposes while was not willing to guarantee the benefits from future treatments.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had donated more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more talks to reach a agreement acceptable to all parties so the nation's critical HIV treatment initiative can proceed.
Broader Background
This rejection follows a similar case in neighbouring Kenya, where a high court halted a similar health funding agreement after legal challenges were filed about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had administered assistance for the US government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral deals to boost openness and responsibility.
Based on reports, 16 African countries have so far agreed to these new health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through American-funded programmes," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no corresponding assurance of access to any medical innovations – such as new medicines or tests – that could result from that shared data," he stated.
"In essence, our country would supply the basic resources for scientific discovery without any assurance that the final treatments would be available to our people if a future pandemic emerge."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were disrupting frameworks previously established through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This mechanism is designed to ensure that when a country provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the capability to create them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We encourage ongoing dialogue with our American counterparts on how future co-operation might be arranged in a manner that respects the sovereignty and interests of each country."
Medical Community Response
A leading public health body said it recognised the government's concerns, but urged that negotiations should continue considering much of the country's HIV programmes depended on international support.
"Where specific concerns arise, such as those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," the group said.
This impasse emphasises the continuing challenges between accepting vital international aid and safeguarding a country's data in an increasingly data-driven world.